International Journal of Endocrinology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：编辑比较友好 2021.7月投稿 2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242186, encodeId=d8fa124218668, content=偏重的研究方向：糖尿病;临床 经验分享：请问大家这个期刊可以发表病例报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:58:08 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242184, encodeId=4d98124218454, content=大家知道这个杂志可以发表病例报道吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:50:02 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977472, encodeId=63869e747242, content=审稿速度:3.0 经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqxL5D7g0iavzmDxZpFqwxx5lZX6HQmvj8ibHNceBs6uDuljQQMqu6H7JYHvLrsib8ZHJ8fGtLaAP1gQ/132, createdBy=bc112010878, createdName=Dr.欧, createdTime=Mon Jun 28 07:32:11 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212530, encodeId=1b681212530cd, content=从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Tue Apr 19 15:01:17 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199164, encodeId=828e1199164d9, content=审稿速度:3.0 经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdd05262162, createdName=14804cf5m16暂无昵称, createdTime=Thu Mar 03 20:17:52 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=)]

2022-09-28 ms5000000380461904

审稿速度:3.0 | 投稿命中率:75.0
经验分享：编辑比较友好
2021.7月投稿
2021.10月接受

73 0

[GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：编辑比较友好 2021.7月投稿 2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242186, encodeId=d8fa124218668, content=偏重的研究方向：糖尿病;临床 经验分享：请问大家这个期刊可以发表病例报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:58:08 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242184, encodeId=4d98124218454, content=大家知道这个杂志可以发表病例报道吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:50:02 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977472, encodeId=63869e747242, content=审稿速度:3.0 经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqxL5D7g0iavzmDxZpFqwxx5lZX6HQmvj8ibHNceBs6uDuljQQMqu6H7JYHvLrsib8ZHJ8fGtLaAP1gQ/132, createdBy=bc112010878, createdName=Dr.欧, createdTime=Mon Jun 28 07:32:11 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212530, encodeId=1b681212530cd, content=从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Tue Apr 19 15:01:17 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199164, encodeId=828e1199164d9, content=审稿速度:3.0 经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdd05262162, createdName=14804cf5m16暂无昵称, createdTime=Thu Mar 03 20:17:52 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=)]

2022-08-30 ms8000001575248306

偏重的研究方向：糖尿病;临床
经验分享：请问大家这个期刊可以发表病例报告吗

59 0

[GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：编辑比较友好 2021.7月投稿 2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242186, encodeId=d8fa124218668, content=偏重的研究方向：糖尿病;临床 经验分享：请问大家这个期刊可以发表病例报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:58:08 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242184, encodeId=4d98124218454, content=大家知道这个杂志可以发表病例报道吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:50:02 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977472, encodeId=63869e747242, content=审稿速度:3.0 经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqxL5D7g0iavzmDxZpFqwxx5lZX6HQmvj8ibHNceBs6uDuljQQMqu6H7JYHvLrsib8ZHJ8fGtLaAP1gQ/132, createdBy=bc112010878, createdName=Dr.欧, createdTime=Mon Jun 28 07:32:11 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212530, encodeId=1b681212530cd, content=从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Tue Apr 19 15:01:17 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199164, encodeId=828e1199164d9, content=审稿速度:3.0 经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdd05262162, createdName=14804cf5m16暂无昵称, createdTime=Thu Mar 03 20:17:52 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=)]

2022-08-30 ms8000001575248306

大家知道这个杂志可以发表病例报道吗

58 0

[GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：编辑比较友好 2021.7月投稿 2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242186, encodeId=d8fa124218668, content=偏重的研究方向：糖尿病;临床 经验分享：请问大家这个期刊可以发表病例报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:58:08 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242184, encodeId=4d98124218454, content=大家知道这个杂志可以发表病例报道吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:50:02 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977472, encodeId=63869e747242, content=审稿速度:3.0 经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqxL5D7g0iavzmDxZpFqwxx5lZX6HQmvj8ibHNceBs6uDuljQQMqu6H7JYHvLrsib8ZHJ8fGtLaAP1gQ/132, createdBy=bc112010878, createdName=Dr.欧, createdTime=Mon Jun 28 07:32:11 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212530, encodeId=1b681212530cd, content=从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Tue Apr 19 15:01:17 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199164, encodeId=828e1199164d9, content=审稿速度:3.0 经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdd05262162, createdName=14804cf5m16暂无昵称, createdTime=Thu Mar 03 20:17:52 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=)]

2022-07-07 ms8000001001905278

有人知道现在得版面费是多少吗

51 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：编辑比较友好 2021.7月投稿 2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242186, encodeId=d8fa124218668, content=偏重的研究方向：糖尿病;临床 经验分享：请问大家这个期刊可以发表病例报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:58:08 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242184, encodeId=4d98124218454, content=大家知道这个杂志可以发表病例报道吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:50:02 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977472, encodeId=63869e747242, content=审稿速度:3.0 经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqxL5D7g0iavzmDxZpFqwxx5lZX6HQmvj8ibHNceBs6uDuljQQMqu6H7JYHvLrsib8ZHJ8fGtLaAP1gQ/132, createdBy=bc112010878, createdName=Dr.欧, createdTime=Mon Jun 28 07:32:11 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212530, encodeId=1b681212530cd, content=从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Tue Apr 19 15:01:17 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199164, encodeId=828e1199164d9, content=审稿速度:3.0 经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdd05262162, createdName=14804cf5m16暂无昵称, createdTime=Thu Mar 03 20:17:52 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=)]

2022-03-17 14755044m78暂无昵称

大家的reviewer invited 都持续了多久啊请问

75 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：编辑比较友好 2021.7月投稿 2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242186, encodeId=d8fa124218668, content=偏重的研究方向：糖尿病;临床 经验分享：请问大家这个期刊可以发表病例报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:58:08 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242184, encodeId=4d98124218454, content=大家知道这个杂志可以发表病例报道吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:50:02 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977472, encodeId=63869e747242, content=审稿速度:3.0 经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqxL5D7g0iavzmDxZpFqwxx5lZX6HQmvj8ibHNceBs6uDuljQQMqu6H7JYHvLrsib8ZHJ8fGtLaAP1gQ/132, createdBy=bc112010878, createdName=Dr.欧, createdTime=Mon Jun 28 07:32:11 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212530, encodeId=1b681212530cd, content=从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Tue Apr 19 15:01:17 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199164, encodeId=828e1199164d9, content=审稿速度:3.0 经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdd05262162, createdName=14804cf5m16暂无昵称, createdTime=Thu Mar 03 20:17:52 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=)]

2022-05-10 ms8000001987505662

这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛

46 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：编辑比较友好 2021.7月投稿 2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242186, encodeId=d8fa124218668, content=偏重的研究方向：糖尿病;临床 经验分享：请问大家这个期刊可以发表病例报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:58:08 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242184, encodeId=4d98124218454, content=大家知道这个杂志可以发表病例报道吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:50:02 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977472, encodeId=63869e747242, content=审稿速度:3.0 经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqxL5D7g0iavzmDxZpFqwxx5lZX6HQmvj8ibHNceBs6uDuljQQMqu6H7JYHvLrsib8ZHJ8fGtLaAP1gQ/132, createdBy=bc112010878, createdName=Dr.欧, createdTime=Mon Jun 28 07:32:11 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212530, encodeId=1b681212530cd, content=从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Tue Apr 19 15:01:17 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199164, encodeId=828e1199164d9, content=审稿速度:3.0 经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdd05262162, createdName=14804cf5m16暂无昵称, createdTime=Thu Mar 03 20:17:52 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=)]

2021-06-28 Dr.欧

审稿速度:3.0
经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？

76 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：编辑比较友好 2021.7月投稿 2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242186, encodeId=d8fa124218668, content=偏重的研究方向：糖尿病;临床 经验分享：请问大家这个期刊可以发表病例报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:58:08 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242184, encodeId=4d98124218454, content=大家知道这个杂志可以发表病例报道吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:50:02 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977472, encodeId=63869e747242, content=审稿速度:3.0 经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqxL5D7g0iavzmDxZpFqwxx5lZX6HQmvj8ibHNceBs6uDuljQQMqu6H7JYHvLrsib8ZHJ8fGtLaAP1gQ/132, createdBy=bc112010878, createdName=Dr.欧, createdTime=Mon Jun 28 07:32:11 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212530, encodeId=1b681212530cd, content=从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Tue Apr 19 15:01:17 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199164, encodeId=828e1199164d9, content=审稿速度:3.0 经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdd05262162, createdName=14804cf5m16暂无昵称, createdTime=Thu Mar 03 20:17:52 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=)]

2022-04-19 1215fa24m64(暂无昵称)

从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？

63 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：编辑比较友好 2021.7月投稿 2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242186, encodeId=d8fa124218668, content=偏重的研究方向：糖尿病;临床 经验分享：请问大家这个期刊可以发表病例报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:58:08 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242184, encodeId=4d98124218454, content=大家知道这个杂志可以发表病例报道吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:50:02 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977472, encodeId=63869e747242, content=审稿速度:3.0 经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqxL5D7g0iavzmDxZpFqwxx5lZX6HQmvj8ibHNceBs6uDuljQQMqu6H7JYHvLrsib8ZHJ8fGtLaAP1gQ/132, createdBy=bc112010878, createdName=Dr.欧, createdTime=Mon Jun 28 07:32:11 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212530, encodeId=1b681212530cd, content=从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Tue Apr 19 15:01:17 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199164, encodeId=828e1199164d9, content=审稿速度:3.0 经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdd05262162, createdName=14804cf5m16暂无昵称, createdTime=Thu Mar 03 20:17:52 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=)]

2022-03-03 14804cf5m16暂无昵称

审稿速度:3.0
经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。

65 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：编辑比较友好 2021.7月投稿 2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242186, encodeId=d8fa124218668, content=偏重的研究方向：糖尿病;临床 经验分享：请问大家这个期刊可以发表病例报告吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:58:08 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242184, encodeId=4d98124218454, content=大家知道这个杂志可以发表病例报道吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bad08293172, createdName=ms8000001575248306, createdTime=Tue Aug 30 23:50:02 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977472, encodeId=63869e747242, content=审稿速度:3.0 经验分享：请问这个杂志的返修上传稿件的界面在哪里呀？我在官网没找到上传返修稿件的入口，是直接邮件发给让修改的编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqxL5D7g0iavzmDxZpFqwxx5lZX6HQmvj8ibHNceBs6uDuljQQMqu6H7JYHvLrsib8ZHJ8fGtLaAP1gQ/132, createdBy=bc112010878, createdName=Dr.欧, createdTime=Mon Jun 28 07:32:11 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212530, encodeId=1b681212530cd, content=从开始投稿就是under review，一般这个状态要持续多久啊？是还没有分配编辑吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Tue Apr 19 15:01:17 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199164, encodeId=828e1199164d9, content=审稿速度:3.0 经验分享：目前还没有出结果，就是和大家分享下有点曲折的投稿过程。刚开始投稿时被拒稿了，貌似说我查重太高了，我想想只好作罢，开始寻找别的杂志，然后找了一家，发现也要查重，还是和这家杂志一样的查重系统。这时候才意识到要降重，这时候已经被拒稿1周多，我心有不甘，就回了编辑一封信，大意是，我降重了以后能不能给个机会再投稿一次，编辑竟然同意了。等了3个月收到大修意见，然后修改了1个月，目前重新提交2天后就变成PENDING APPROVAL，不知结果如何，希望有个好结果吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdd05262162, createdName=14804cf5m16暂无昵称, createdTime=Thu Mar 03 20:17:52 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=)]

2022-03-10 14755044m78暂无昵称

请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！

40 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务